Integrum AB Class B (INTEG.B) AI Stock Analysis

• Market Cap: €293.13M
• Dividend Yield: N/A
• Average Volume (3M): 533.77K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.41
• Revenue Growth: -5.63%
• EPS Growth: -1373.99%
• Country: SE
• Employees: 36
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.47
• Shares Outstanding: 20,694,328
• 10 Day Avg. Volume: 1,416,212
• 30 Day Avg. Volume: 533,768
• PEG Ratio: 0.01
• Price to Book (P/B): 1.64
• Price to Sales (P/S): 3.20
• P/FCF Ratio: -5.76
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €15.02
• Price Target Upside: 9.28% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: kr15.00 ▲(9.17% Upside)

Integrum AB Class B faces significant challenges, primarily in financial performance and technical analysis. The company's strong gross profit margin is overshadowed by negative profitability and cash flow issues. Technical indicators show bearish momentum, and the valuation is unattractive due to a negative P/E ratio. These factors contribute to a low overall stock score.

Integrum AB Class B Business Overview & Revenue Model

Company Description

Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoiding bone fractures from accidental loads. The company also provides Neuromotus, a technology that is used for therapy to reduce phantom limb pain after an amputation. It sells its implant systems to hospitals, clinics, and orthopedists worldwide. The company was founded in 1962 and is headquartered in Mölndal, Sweden.

How the Company Makes Money

Integrum AB generates revenue primarily through the sale of its OPRA Implant System to healthcare providers and clinics around the world. The company earns money by manufacturing and distributing these advanced prosthetic solutions, which are typically covered by insurance providers or paid for by healthcare institutions. Additionally, Integrum may engage in strategic partnerships with medical device companies or healthcare organizations to expand the adoption of its technology. The company's earnings are also bolstered by ongoing research and development efforts, which may lead to new product offerings or enhancements to existing systems, thus attracting more customers.

Integrum AB Class B Financial Statement Overview

Summary

Integrum AB is facing financial challenges with declining revenues and increasing losses, as seen in the income statement. The company maintains a stable balance sheet with a strong equity position, but negative cash flow trends indicate liquidity concerns.

Income Statement

Integrum AB's income statement shows a declining trend in revenue with a significant drop from 2024 to 2025. The gross profit margin remains relatively high, indicating efficient cost management in production. However, the company has faced increasing operating losses, as seen in the negative EBIT and EBITDA margins, signaling challenges in covering operational expenses. Net profit margins have also deteriorated, reflecting overall financial struggles in maintaining profitability.

Balance Sheet

The balance sheet demonstrates a strong equity position with a high equity ratio, indicating financial stability and a lower reliance on debt. The debt-to-equity ratio is low, which is favorable and shows prudent financial management. Return on equity, however, is negative, reflecting the company's inability to generate profit from its equity base. Overall, the balance sheet is stable with potential for leveraging equity for growth.

Cash Flow

Cash flow analysis reveals consistent challenges in generating positive operating cash flow, contributing to negative free cash flow. The operating cash flow to net income ratio indicates difficulties in converting income to cash. Financing activities have been a source of cash, but reliance on external financing could pose risks if not managed carefully. There is a negative trend in free cash flow growth, pointing to potential liquidity concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	96.44M	91.10M	104.12M	74.27M	55.72M	43.09M
Gross Profit	76.24M	75.38M	91.26M	60.84M	46.56M	34.89M
EBITDA	-35.80M	-35.50M	8.76M	-20.24M	2.60M	-1.59M
Net Income	-31.40M	-30.85M	4.03M	-16.18M	21.27M	-2.14M
Balance Sheet
Total Assets	193.79M	203.25M	164.86M	165.17M	180.44M	37.21M
Cash, Cash Equivalents and Short-Term Investments	27.19M	39.60M	16.90M	41.92M	75.34M	7.66M
Total Debt	4.43M	4.84M	6.42M	7.92M	580.89K	485.92K
Total Liabilities	25.68M	25.38M	22.07M	21.64M	20.70M	12.91M
Stockholders Equity	168.11M	177.88M	142.79M	143.53M	159.74M	24.29M
Cash Flow
Free Cash Flow	-46.01M	-50.59M	-24.37M	-36.50M	-49.55M	-7.47M
Operating Cash Flow	-33.27M	-37.70M	-12.74M	-25.10M	-20.28M	-5.76M
Investing Cash Flow	-12.74M	-12.89M	-11.63M	-11.40M	-29.27M	-1.71M
Financing Cash Flow	27.02M	73.29M	-648.54K	3.08M	117.23M	2.06M

Integrum AB Class B Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 13.74
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:INTEG.B, the sentiment is Negative. The current price of 13.74 is below the 20-day moving average (MA) of 30.96, below the 50-day MA of 37.15, and below the 200-day MA of 22.33, indicating a bearish trend. The MACD of -7.12 indicates Positive momentum. The RSI at 8.73 is Positive, neither overbought nor oversold. The STOCH value of 1.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:INTEG.B.

Integrum AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	62 Neutral	kr1.01B	39.26	7.56%	―	-10.34%	-59.69%
ACARIX	46 Neutral	kr343.17M	-5.27	―	―	-11.11%	48.03%
BACTI.B	45 Neutral	kr714.90M	-38.78	-5.96%	―	11.60%	75.76%
MNTC	45 Neutral	kr331.88M	-5.44	-58.55%	―	-6.82%	-449.86%
SEZI	43 Neutral	kr988.88M	-6.51	-34.03%	―	71.41%	17.26%
INTEG.B	43 Neutral	€293.13M	―	-18.35%	―	-5.63%	-1373.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%